Is there a need for new antifungal agents

Clinical Microbiology and Infection

Volumn 6, Issue SUPPL. 2, 2000, Pages 23-28

  De Pauw, B E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allylamines; Amphotericin B; Antifungals; Aspergillus infection; Candida infection; Fluoropyrimidines; Polyenes; Triazoles; (1,3) D glucan synthesis inhibitors

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CYCLOPEPTIDE; ECHINOCANDIN B; FUNGAL PROTEIN; PEPTIDE;

ANIMAL; HUMAN; MYCOSIS; REVIEW;

AMPHOTERICIN B; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; FUNGAL PROTEINS; HUMANS; MYCOSES; PEPTIDES; PEPTIDES, CYCLIC;

EID: 9144223419     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2000.00006.x     Document Type: Article

References (16)

1. Dixon DM, McNeil MM, Cohen ML, Gellin BG, La Montagne JR. Fungal infections: a growing threat. Public Health Rep 1996; 111: 226-35.
2. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499-511.
3. Wiley JM, Smith N, Leventhal BG et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990; 8: 280-6.
4. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18: 525-32.
5. Ruutu P, Valtonen V, Tiitanen L et al. An outbreak of invasive aspergillosis in a haematologic unit. Scand J Infect Dis 1987; 19: 347-51.
6. Gaspar C, Mariano A, Cuesta J et al. Outbreak of invasive pulmonary mycosis in neutropenic hematologic patients in relation to remodelling construction work. Enferm Infect Microbiol Clin 1999; 17: 113-18.
7. Minamoto GY, Rosenberg AS. Fungal infections in patients with acquired immunodeficiency syndrome. Med Clin North Am 1997; 81: 381-409.
8. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16: 677-88.
9. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10: 86-124.
10. Pruitt BA Jr, McManus AT, Kim SH, Goodwin CW. Burn wounds infections: current status, World J Surg 1998; 22: 135-15.
11. de Pauw BE, Meis JF. Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer 1998; 6: 31-8.
12. Meyer RD. Current role of therapy with Amphotericin B. Clin. Infect Dis 1992; 14: (Suppl. 1) 5154-60.
13. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf 1990; 5: 94-108.
14. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6: 154-64.
15. Miano-Mason TM. Mechanisms and management of amphotericin B-induced nephrotoxicity. Cancer Pract 1997; 5: 176-81.
16. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Phannacokinet 1992; 23: 279-91.